CA
TEVA icon

Cetera Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Cetera Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-120,677
Closed -$909K – 1797
2023
Q2 		$909K Sell
120,677
-44,810
-27% -$363K 0.01% 751
2023
Q1 		$1.46M Buy
165,487
+145,112
+712% +$1.43M 0.02% 555
2022
Q4 		$186K Sell
20,375
-193,620
-90% -$1.69M ﹤0.01% 1461
2022
Q3 		$1.73M Buy
213,995
+19,706
+10% +$174K 0.05% 397
2022
Q2 		$1.46M Buy
194,289
+90,952
+88% +$792K 0.03% 465
2022
Q1 		$970K Sell
103,337
-91,157
-47% -$761K 0.02% 625
2021
Q4 		$1.56M Buy
194,494
+157,087
+420% +$1.42M 0.03% 463
2021
Q3 		$364K Sell
37,407
-13,139
-26% -$123K 0.01% 1007
2021
Q2 		$500K Sell
50,546
-5,925
-10% -$62.7K 0.01% 820
2021
Q1 		$652K Buy
56,471
+19,406
+52% +$223K 0.02% 632
2020
Q4 		$358K Sell
37,065
-14,543
-28% -$139K 0.01% 765
2020
Q3 		$465K Sell
51,608
-73,082
-59% -$773K 0.02% 589
2020
Q2 		$1.54M Sell
124,690
-14,257
-10% -$161K 0.07% 271
2020
Q1 		$1.25M Buy
138,947
+13,657
+11% +$140K 0.07% 285
2019
Q4 		$1.24M Buy
125,290
+46,307
+59% +$413K 0.05% 325
2019
Q3 		$540K Buy
78,983
+33,414
+73% +$256K 0.02% 519
2019
Q2 		$420K Buy
45,569
+24,194
+113% +$292K 0.02% 609
2019
Q1 		$338K Sell
21,375
-796
-4% -$14K 0.02% 608
2018
Q4 		$341K Sell
22,171
-3,349
-13% -$68.7K 0.02% 595
2018
Q3 		$548K Buy
+25,520
New +$592K 0.03% 528
2016
Q4 		– Sell
-9,634
Closed -$444K – 805
2016
Q3 		$444K Sell
9,634
-12,410
-56% -$647K 0.03% 446
2016
Q2 		$1.11M Sell
22,044
-1,842
-8% -$98.1K 0.09% 242
2016
Q1 		$1.28M Sell
23,886
-2,176
-8% -$128K 0.11% 199
2015
Q4 		$1.71M Buy
26,062
+1,190
+5% +$73.5K 0.14% 169
2015
Q3 		$1.41M Sell
24,872
-104
-0.4% -$6.74K 0.13% 173
2015
Q2 		$1.48M Buy
24,976
+1,807
+8% +$111K 0.13% 181
2015
Q1 		$1.44M Sell
23,169
-2,296
-9% -$133K 0.13% 186
2014
Q4 		$1.48M Buy
25,465
+1,242
+5% +$69.2K 0.14% 174
2014
Q3 		$1.31M Buy
24,223
+933
+4% +$49.4K 0.1% 178
2014
Q2 		$1.22M Buy
+23,290
New +$1.19M 0.14% 185

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Cetera Advisors's TEVA Position: Q3 2023 in Review

Cetera Advisors sold out of Teva Pharmaceuticals (TEVA) in Q3 2023, closing a stake of 120,677 shares — an estimated $909K sold.

Cetera Advisors first reported a position in TEVA in Q2 2014 and held it in 30 quarters. The position peaked at $1.73M in Q3 2022. 435 funds tracked by Wall St. Rank hold TEVA as of Q3 2023.

  • Cetera Advisors reported no remaining Teva Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Cetera Advisors sold 120,677 Teva Pharmaceuticals shares in Q3 2023, an estimated $909K.
  • Cetera Advisors first reported a position in Teva Pharmaceuticals in Q2 2014 and held it in 30 quarters.
  • Cetera Advisors's Teva Pharmaceuticals position peaked at $1.73M in Q3 2022.
  • 435 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2023.

Based on Cetera Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.